title: Practical management of bevacizumab-related toxicities in glioblastoma.
abstract: Bevacizumab, currently an option for treatment of different types of tumors including glioblastoma, has a peculiar toxicity profile related to its antiangiogenic effect. Because some bevacizumab-related adverse events can be life threatening, it is important to identify risk factors and to establish treatment protocols to minimize treatment-related morbidity and mortality. In glioblastoma patients, the risk of developing certain side effects, such as gastrointestinal perforation, venous thromboembolism, and intracranial hemorrhages, is slightly higher than in patients treated with bevacizumab for other tumor types. We performed a systematic review of the side effects of bevacizumab and their incidence, causal mechanisms, and available treatments. Finally, we identified risk factors and proposed preventive and therapeutic measures for these adverse events.
authors.affiliation: Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy alba.brandes@yahoo.it.
authors.forename: Alba A
authors.initials: AA
authors.lastname: Brandes
authors.affiliation: Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Bartolotti
authors.affiliation: Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy.
authors.forename: Alicia
authors.initials: A
authors.lastname: Tosoni
authors.affiliation: Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy.
authors.forename: Rosalba
authors.initials: R
authors.lastname: Poggi
authors.affiliation: Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy.
authors.forename: Enrico
authors.initials: E
authors.lastname: Franceschi
mesh_terms: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab / Q000008:administration & dosage / Q000009:adverse effects*; D019468:Disease Management; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D054556:Venous Thromboembolism / Q000139:chemically induced / Q000473:pathology*
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
keywords: Antiangiogenic; Bevacizumab; Side effects; Toxicity